Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Efficacy Evaluation Post Intravenous Infusion of Activated NK Cells in Recurrent and Refractory High-risk Neuroblastoma Patients

NCT06674265 is registered in ClinicalTrials.gov with Marzieh Ebrahimi as lead sponsor.

NCT NCT06674265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06674265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Efficacy Evaluation Post Intravenous Infusion of Activated NK Cells in Recurrent and Refractory High-risk Neuroblastoma Patients
Lead sponsor
Marzieh Ebrahimi
Phase
Phase 1
Overall status
Recruiting
Start date
November 10, 2024
Completion date
November 30, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma (nb), neuroblastoma in children, neuroblastoma, recurrent, refractory